A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Trial Profile

A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Apitolisib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms MAGGIE study
  • Sponsors Genentech
  • Most Recent Events

    • 07 Sep 2016 Results published in the Cancer.
    • 22 Jul 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
    • 20 Aug 2013 Planned End Date changed from 1 Dec 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top